Literature DB >> 6583437

Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary.

A P Wilson.   

Abstract

An established cell line derived from the ascites of a patient with serous cystadenocarcinoma of the ovary has been characterized. Features studied included morphology, ultrastructure, clonogenicity in soft agar, population doubling time, karyotype, and chemosensitivity. The results indicated that the cells growing in culture were malignant ovarian tumor cells. These cells retained the ability to form free-floating cysts in culture, which were also present in the original ascitic fluid. The cell line had a chromosome number of 80-92 with no distinct mode and 15 stable markers. At passage 4 the cell line showed resistance to doxorubicin [adriamycin (ADM)], phosphoramide mustard (PM), and cisplatin [cis-dichlorodiammineplatinum(II)] (CIS) but rapidly reverted to CIS sensitivity. At passage 25 the cell line was still resistant to ADM and PM, but by passage 59 sensitivity to these drugs appeared to have increased. Frozen cells from passage 15 onward are available.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6583437

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  28 in total

1.  New human ovarian cell line OVCCR1/sf in serum-free medium.

Authors:  S Jozan; H Roché; F Cheutin; M Carton; B Salles
Journal:  In Vitro Cell Dev Biol       Date:  1992 Nov-Dec

2.  Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer.

Authors:  Vijayalakshmi N Ayyagari; Nancy A Johnston; Laurent Brard
Journal:  Anticancer Drugs       Date:  2016-07       Impact factor: 2.248

3.  Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines--with special reference to cisplatin.

Authors:  F Bernges; W J Zeller
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.

Authors:  Carsten Denkert; Martin Köbel; Sören Pest; Ines Koch; Stefan Berger; Michael Schwabe; Antje Siegert; Angela Reles; Bernd Klosterhalfen; Steffen Hauptmann
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

5.  Use of XTT for quantitating clonogenic growth in soft agar.

Authors:  M F Dent; L Hubbold; H Radford; A P Wilson
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

6.  Inhibition of O6-alkylguanine-DNA alkyltransferase in animal and human ovarian tumor cell lines by O6-benzylguanine and sensitization to BCNU.

Authors:  A Magull-Seltenreich; W J Zeller
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Establishment and characterization of two new human ovarian cancer cell lines UWOV1 and UWOV2 and a subline UWOV2 (Sf) growing in serum-free conditions: growth characteristics, biochemical, and cytogenetic studies.

Authors:  T Golombick; R Dansey; W R Bezwoda; J Rosendorff
Journal:  In Vitro Cell Dev Biol       Date:  1990-05

8.  Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines.

Authors:  Andrea Schröpfer; Ulrike Kammerer; Michaela Kapp; Johannes Dietl; Sonja Feix; Jelena Anacker
Journal:  BMC Cancer       Date:  2010-10-13       Impact factor: 4.430

9.  Synthesis, Structure, and Antiproliferative Activity of Three Gallium(III) Azole Complexes.

Authors:  Stergios Zanias; Giannis S Papaefstathiou; Catherine P Raptopoulou; Konstantinos T Papazisis; Vasiliki Vala; Dimitra Zambouli; Alexandros H Kortsaris; Dimitrios A Kyriakidis; Theodoros F Zafiropoulos
Journal:  Bioinorg Chem Appl       Date:  2010-07-18       Impact factor: 7.778

10.  Effect of interferon gamma and tumour necrosis factor alpha on sensitivity to cisplatin in ovarian carcinoma cell lines.

Authors:  S Clark; M A McGuckin; T Hurst; B G Ward
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.